{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:38:46Z","timestamp":1794512326193,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2018 \u2013ID. 21354 project"],"award-info":[{"award-number":["IG 2018 \u2013ID. 21354 project"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["5 per Mille 2019 - ID. 22759 program"],"award-info":[{"award-number":["5 per Mille 2019 - ID. 22759 program"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["BIGID219MON2"],"award-info":[{"award-number":["BIGID219MON2"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC IZSVE 08\/06"],"award-info":[{"award-number":["RC IZSVE 08\/06"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the main goals of vaccine research is the development of adjuvants that can enhance immune responses and are both safe and biocompatible. We explored the application of the natural polymer hyaluronan (HA) as a promising immunological adjuvant for protein-based vaccines. Chemical conjugation of HA to antigens strongly increased their immunogenicity, reduced booster requirements, and allowed antigen dose sparing. HA-based bioconjugates stimulated robust and long-lasting humoral responses without the addition of other immunostimulatory compounds and proved highly efficient when compared to other adjuvants. Due to its intrinsic biocompatibility, HA allowed the exploitation of different injection routes and did not induce inflammation at the inoculation site. This polymer promoted rapid translocation of the antigen to draining lymph nodes, thus facilitating encounters with antigen-presenting cells. Overall, HA can be regarded as an effective and biocompatible adjuvant to be exploited for the design of a wide variety of vaccines.<\/jats:p>","DOI":"10.1038\/s41423-021-00667-y","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T08:03:57Z","timestamp":1616573037000},"page":"1197-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines"],"prefix":"10.1038","volume":"18","author":[{"given":"Anna","family":"Dalla Piet\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Carpanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Grigoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dalla Santa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Kristian","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-3616","authenticated-orcid":false,"given":"Laura","family":"Mel\u00e9ndez-Alafort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-1933","authenticated-orcid":false,"given":"Paola","family":"De Benedictis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Pasut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Monia","family":"Montagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-8386","authenticated-orcid":false,"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/polym10070701","volume":"10","author":"A Fallacara","year":"2018","unstructured":"Fallacara, A., Baldini, E., Manfredini, S. & Vertuani, S. Hyaluronic acid in the third millennium. Polymers 10, 701 (2018).","journal-title":"Polymers"},{"key":"667_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.biomaterials.2017.01.029","volume":"123","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Hyaluronate and its derivatives for customized biomedical applications. Biomaterials 123, 155\u2013171 (2017).","journal-title":"Biomaterials"},{"key":"667_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2016.06.033","volume":"236","author":"IM Montagner","year":"2016","unstructured":"Montagner, I. M. et al. A site-selective hyaluronan-interferon\u03b12a conjugate for the treatment of ovarian cancer. J. Control. Release 236, 79\u201389 (2016).","journal-title":"J. Control. Release"},{"key":"667_CR4","doi-asserted-by":"publisher","first-page":"e112240","DOI":"10.1371\/journal.pone.0112240","volume":"9","author":"IM Montagner","year":"2014","unstructured":"Montagner, I. M. et al. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS ONE 9, e112240 (2014).","journal-title":"PLoS ONE"},{"key":"667_CR5","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1158\/1078-0432.CCR-07-2019","volume":"14","author":"A Banzato","year":"2008","unstructured":"Banzato, A. et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14, 3598\u20133606 (2008).","journal-title":"Clin. Cancer Res."},{"key":"667_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ejcb.2006.05.009","volume":"85","author":"R Stern","year":"2006","unstructured":"Stern, R., Asari, A. & Sugahara, K. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 85, 699\u2013715 (2006).","journal-title":"Eur. J. Cell Biol."},{"key":"667_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.addr.2015.10.017","volume":"97","author":"J Liang","year":"2016","unstructured":"Liang, J., Jiang, D. & Noble, P. W. Hyaluronan as a therapeutic target in human diseases. Adv. Drug Deliv. Rev. 97, 186\u2013203 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"42802","DOI":"10.1074\/jbc.M307201200","volume":"278","author":"JA Weigel","year":"2003","unstructured":"Weigel, J. A. & Weigel, P. H. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 278, 42802\u201342811 (2003).","journal-title":"J. Biol. Chem."},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fimmu.2016.00039","volume":"7","author":"D Naor","year":"2016","unstructured":"Naor, D. Editorial: interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front. Immunol. 7, 10\u201313 (2016).","journal-title":"Front. Immunol."},{"key":"667_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1083\/jcb.144.4.789","volume":"144","author":"S Banerji","year":"1999","unstructured":"Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789\u2013801 (1999).","journal-title":"J. Cell Biol."},{"key":"667_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00150","volume":"6","author":"SSM Lee-Sayer","year":"2015","unstructured":"Lee-Sayer, S. S. M. et al. The where, when, how, and why of hyaluronan binding by immune cells. Front. Immunol. 6, 1\u201312 (2015).","journal-title":"Front. Immunol."},{"key":"667_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1385\/IR:31:3:189","volume":"31","author":"ME Mummert","year":"2005","unstructured":"Mummert, M. E. Immunologic roles of hyaluronan. Immunol. Res. 31, 189\u2013206 (2005).","journal-title":"Immunol. Res."},{"key":"667_CR13","doi-asserted-by":"publisher","first-page":"7832","DOI":"10.4049\/jimmunol.0901683","volume":"183","author":"SS Chandran","year":"2009","unstructured":"Chandran, S. S., Verhoeven, D., Teijaro, J. R., Fenton, M. J. & Farber, D. L. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J. Immunol. 183, 7832\u20137841 (2009).","journal-title":"J. Immunol."},{"key":"667_CR14","first-page":"3831","volume":"71","author":"S Adams","year":"2009","unstructured":"Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 71, 3831\u20133840 (2009).","journal-title":"Immunotherapy"},{"key":"667_CR15","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.4049\/jimmunol.169.8.4322","volume":"169","author":"ME Mummert","year":"2002","unstructured":"Mummert, M. E. et al. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J. Immunol. 169, 4322\u20134331 (2002).","journal-title":"J. Immunol."},{"key":"667_CR16","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/adfm.201504879","volume":"26","author":"KS Kim","year":"2016","unstructured":"Kim, K. S. et al. Noninvasive transdermal vaccination using hyaluronan nanocarriers and laser adjuvant. Adv. Funct. Mater. 26, 2512\u20132522 (2016).","journal-title":"Adv. Funct. Mater."},{"key":"667_CR17","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1016\/j.vaccine.2008.09.045","volume":"26","author":"A Lahiri","year":"2008","unstructured":"Lahiri, A., Das, P. & Chakravortty, D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26, 6777\u20136783 (2008).","journal-title":"Vaccine"},{"key":"667_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178\u2013196 (2011).","journal-title":"Immunol. Rev."},{"key":"667_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2016.40","volume":"5","author":"Y Wen","year":"2016","unstructured":"Wen, Y. & Shi, Y. Alum: an old dog with new tricks. Emerg. Microbes Infect. 5, 1\u20135 (2016).","journal-title":"Emerg. Microbes Infect."},{"key":"667_CR20","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1016\/j.vaccine.2011.04.046","volume":"29","author":"N Gar\u00e7on","year":"2011","unstructured":"Gar\u00e7on, N., Segal, L., Tavares, F. & Van Mechelen, M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 29, 4453\u20134459 (2011).","journal-title":"Vaccine"},{"key":"667_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny, M. A. et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 387, 367\u2013375 (2016).","journal-title":"Lancet"},{"key":"667_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1021\/acs.bioconjchem.5b00285","volume":"26","author":"H Shinchi","year":"2015","unstructured":"Shinchi, H. et al. Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides. Bioconjug. Chem. 26, 1713\u20131723 (2015).","journal-title":"Bioconjug. Chem."},{"key":"667_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/cmdc.201500088","volume":"10","author":"D Gao","year":"2015","unstructured":"Gao, D. et al. Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens. ChemMedChem 10, 977\u2013980 (2015).","journal-title":"ChemMedChem"},{"key":"667_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1021\/acs.bioconjchem.7b00808","volume":"29","author":"BJ Ignacio","year":"2018","unstructured":"Ignacio, B. J., Albin, T. J., Esser-Kahn, A. P. & Verdoes, M. Toll-like receptor agonist conjugation: a chemical perspective. Bioconjug. Chem. 29, 587\u2013603 (2018).","journal-title":"Bioconjug. Chem."},{"key":"667_CR25","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.carbpol.2012.11.090","volume":"92","author":"A Mero","year":"2013","unstructured":"Mero, A., Pasqualin, M., Campisi, M., Renier, D. & Pasut, G. Conjugation of hyaluronan to proteins. Carbohydr. Polym. 92, 2163\u20132170 (2013).","journal-title":"Carbohydr. Polym."},{"key":"667_CR26","unstructured":"Meslin, F. X., Kaplan, M. M. & Koprowski, H. in Laboratory Techniques in Rabies (World Health Organization, 1996)."},{"key":"667_CR27","doi-asserted-by":"publisher","first-page":"e1313371","DOI":"10.1080\/2162402X.2017.1313371","volume":"6","author":"A Tosi","year":"2017","unstructured":"Tosi, A. et al. Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology 6, e1313371 (2017).","journal-title":"Oncoimmunology"},{"key":"667_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1128\/jvi.69.3.1895-1902.1995","volume":"69","author":"MK Slifka","year":"1995","unstructured":"Slifka, M. K., Matloubian, M. & Ahmed, R. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69,\u00a01895\u20131902 (1995).","journal-title":"J. Virol"},{"key":"667_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133\u2013134 (1997).","journal-title":"Nature"},{"key":"667_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/eji.201747019","volume":"47","author":"K Pracht","year":"2017","unstructured":"Pracht, K. et al. A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry. Eur. J. Immunol. 47, 1389\u20131392 (2017).","journal-title":"Eur. J. Immunol."},{"key":"667_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/mi.2015.38","volume":"9","author":"A Lemke","year":"2016","unstructured":"Lemke, A. et al. Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice. Mucosal Immunol. 9, 83\u201397 (2016).","journal-title":"Mucosal Immunol."},{"key":"667_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/cei.12841","volume":"186","author":"M Zeng","year":"2016","unstructured":"Zeng, M., Nourishirazi, E., Guinet, E. & Nouri-Shirazi, M. The genetic background influences the cellular and humoral immune responses to vaccines. Clin. Exp. Immunol. 186, 190\u2013204 (2016).","journal-title":"Clin. Exp. Immunol."},{"key":"667_CR33","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.4049\/jimmunol.165.4.1863","volume":"165","author":"CC Termeer","year":"2000","unstructured":"Termeer, C. C. et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J. Immunol. 165, 1863\u20131870 (2000).","journal-title":"J. Immunol."},{"key":"667_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.20001858","volume":"195","author":"C Termeer","year":"2002","unstructured":"Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 195, 99\u2013111 (2002).","journal-title":"J. Exp. Med."},{"key":"667_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","volume":"47","author":"DT O\u2019Hagan","year":"2017","unstructured":"O\u2019Hagan, D. T., Friedland, L. R., Hanon, E. & Didierlaurent, A. M. Towards an evidence based approach for the development of adjuvanted vaccines. Curr. Opin. Immunol. 47, 93\u2013102 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"667_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","volume":"39","author":"G Del Giudice","year":"2018","unstructured":"Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin. Immunol. 39, 14\u201321 (2018).","journal-title":"Semin. Immunol."},{"key":"667_CR37","doi-asserted-by":"publisher","first-page":"eaax2285","DOI":"10.1126\/sciadv.aax2285","volume":"6","author":"M Skwarczynski","year":"2020","unstructured":"Skwarczynski, M. et al. Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. Sci. Adv. 6, eaax2285 (2020).","journal-title":"Sci. Adv."},{"key":"667_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2014.12.007","volume":"199","author":"Y-H Lee","year":"2015","unstructured":"Lee, Y. -H. et al. A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo. J. Control. Release 199, 98\u2013105 (2015).","journal-title":"J. Control. Release"},{"key":"667_CR39","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1016\/j.vaccine.2015.08.006","volume":"33","author":"S Moon","year":"2015","unstructured":"Moon, S., Shin, E. C., Noh, Y. W. & Lim, Y. T. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine. Vaccine 33, 4762\u20134769 (2015).","journal-title":"Vaccine"},{"key":"667_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejpb.2018.11.013","volume":"134","author":"M Leone","year":"2019","unstructured":"Leone, M. et al. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: formulation, physicochemical characterization and immunogenicity assessment. Eur. J. Pharm. Biopharm. 134, 49\u201359 (2019).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"667_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","volume":"30","author":"SG Reed","year":"2009","unstructured":"Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M. New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23\u201332 (2009).","journal-title":"Trends Immunol."},{"key":"667_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.virol.2010.12.016","volume":"411","author":"IJ Amanna","year":"2011","unstructured":"Amanna, I. J. & Slifka, M. K. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 411, 206\u2013215 (2011).","journal-title":"Virology"},{"key":"667_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/nbt.3371","volume":"33","author":"GM Lynn","year":"2015","unstructured":"Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201\u20131210 (2015).","journal-title":"Nat. Biotechnol."},{"key":"667_CR44","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Wang, W. & Wang, S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev. Vaccines 14, 1509\u20131523 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"667_CR45","doi-asserted-by":"publisher","unstructured":"Vasvani, S., Kulkarni, P. & Rawtani, D. Hyaluronic acid: a review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. Int. J. Biol. Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.11.066 (2019).","DOI":"10.1016\/j.ijbiomac.2019.11.066"},{"key":"667_CR46","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1021\/acs.bioconjchem.8b00386","volume":"29","author":"E Yoo","year":"2018","unstructured":"Yoo, E. et al. Hyaluronic acid conjugates of TLR7\/8 agonists for targeted delivery to secondary lymphoid tissue. Bioconjug. Chem. 29, 2741\u20132754 (2018).","journal-title":"Bioconjug. Chem."},{"key":"667_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nature08604","volume":"462","author":"JA Hubbell","year":"2009","unstructured":"Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. Nature 462, 449\u2013460 (2009).","journal-title":"Nature"},{"key":"667_CR48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.177.2.1272","volume":"177","author":"KA Scheibner","year":"2014","unstructured":"Scheibner, K. A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272\u20131281 (2014).","journal-title":"J. Immunol."},{"key":"667_CR49","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1172\/JCI67947","volume":"124","author":"J Muto","year":"2014","unstructured":"Muto, J. et al. Hyaluronan digestion controls DC migration from the skin. J. Clin. Investig. 124, 1309\u20131319 (2014).","journal-title":"J. Clin. Investig."},{"key":"667_CR50","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1080\/21645515.2016.1219003","volume":"12","author":"D Christensen","year":"2016","unstructured":"Christensen, D. Vaccine adjuvants: why and how. Hum. Vaccin. Immunother. 12, 2709\u20132711 (2016).","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00667-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00667-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T06:05:05Z","timestamp":1675058705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-021-00667-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1038\/s41423-021-00667-y","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.P., D.C., I.M.M., and A.R. are inventors on Patent Application No. PCT\/IB2019\/059122 submitted on October 24, 2019 related to \u201cHyaluronic acid as a natural adjuvant for protein and peptide-based vaccines.\u201d All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}